|
Variable
|
Crude HR (95 % CI)
|
p-value
|
Adjusted HR (95 % CI)
|
p-value
|
|---|
|
Age, years
|
1.10
|
(1.10-1.11)
|
<0.0001
|
1.09
|
(1.08-1.10)
|
<0.0001
|
|
Monthly income, NTD
| | | | | | |
|
<= 15000
|
4.85
|
(3.98-5.91)
|
<0.0001
|
1.34
|
(1.08-1.66)
|
0.009
|
|
15001-20000
|
2.25
|
(1.86-2.71)
|
<0.0001
|
1.51
|
(1.25-1.82)
|
<0.0001
|
|
>20000
|
1.00
|
Ref.
| |
1.00
|
Ref.
| |
|
Comorbidity (yes vs. no)
| | | | | | |
|
Hypertension
|
4.48
|
(3.94-5.09)
|
<0.0001
|
1.27
|
(1.09-1.48)
|
0.002
|
|
Hyperlipidemia
|
2.19
|
(1.92-2.50)
|
<0.0001
|
0.83
|
(0.72-0.96)
|
0.01
|
|
Diabetes
|
3.65
|
(3.18-4.19)
|
<0.0001
|
1.59
|
(1.37-1.85)
|
<0.0001
|
|
PAD
|
2.74
|
(2.00-3.74)
|
<0.0001
|
0.99
|
(0.72-1.36)
|
0.96
|
|
Stroke
|
5.40
|
(4.27-6.83)
|
<0.0001
|
1.38
|
(1.08-1.76)
|
0.01
|
|
Osteoporosis
|
3.11
|
(2.70-3.58)
|
<0.0001
|
1.38
|
(1.19-1.59)
|
<0.0001
|
|
Aromatase inhibitor use before the end point
|
1.18
|
(1.00-1.40)
|
0.049
|
0.80
|
(0.68-0.95)
|
0.01
|
- Manually adjusted for tamoxifen use, age, monthly income, comorbidity and aromatase inhibitor use before the end point
- PAD, peripheral artery disease
